A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417) (REQUEST)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00741104

P05417

Details and patient eligibility

About

This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study. Patients will be asked a variety of questions regarding their treatment dosing and disease activity, and then asked whether or not they would consider participating in a dose reduction study. Patients in this study will be described in terms of demographic and disease characteristics.

Full description

Already known Subjects (RA and on at least 12 months ongoing Remicade treatment) from the clinic could participate if they are eligible.

Enrollment: 363 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Rheumatoid arthritis, infliximab maintenance treatment for at least the past 12 months, given written informed consent.

Exclusion criteria

• episodic treatment with infliximab

Trial design

363 participants in 1 patient group

RA patients

Description:

Patients on maintenance therapy for RA with infliximab for \>= the past 12 months.

Treatment:

Drug: Infliximab